The emerging landscape of breast cancer susceptibility

Nature Genetics

Volumn 40, Issue 1, 2008, Pages 17-22

  Stratton, Michael R ^a,b   Rahman, Nazneen ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ALLELE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; DNA REPAIR; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; LINKAGE ANALYSIS; ONCOGENE; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ALLELES; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PENETRANCE;

EID: 37549056200     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2007.53     Document Type: Review

References (55)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 360, 187-195 (2002).
2. Peto, J. & Mack, T.M. High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet. 26, 411-414 (2000).
3. Hall, J.M. et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 1684-1689 (1990).
4. Wooster, R. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265, 2088-2090 (1994).
5. Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
6. Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
7. Thompson, D. & Easton, D.F. Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst. 94, 1358-1365 (2002).
8. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91, 1310-1316 (1999).
9. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer 83, 1301-1308 (2000).
10. Peto, J. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl. Cancer Inst. 91, 943-949 (1999).
11. Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864-5874 (2006).
12. Thompson, D. & Easton, D. The genetic epidemiology of breast cancer genes. J. Mammary Gland Biol. Neoplasia 9, 221-236 (2004).
13. Antoniou, A.C. & Easton, D.F. Models of genetic susceptibility to breast cancer. Oncogene 25, 5898-5905 (2006).
14. Smith, P. et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosom. Cancer 45, 646-655 (2006).
15. Rahman, N. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165-167 (2007).
16. Meijers-Heijboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31, 55-59 (2002).
17. Renwick, A. et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38, 873-875 (2006).
18. Seal, S. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38, 1239-1241 (2006).
19. Erkko, H. et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 446, 316-319 (2007).
20. Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-1093 (2007).
21. Hunter, D.J. et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870-874 (2007).
22. Stacey, S.N. et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39, 865-869 (2007).
23. Ahn, J., Urist, M. & Prives, C. The Chk2 protein kinase. DNA Repair (Amst.) 3, 1039-1047 (2004).
24. Shiloh, Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem. Sci. 31, 402-410 (2006).
25. Peng, M., Litman, R., Jin, Z., Fong, G. & Cantor, S.B. BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene 25, 2245-2253 (2006).
26. Xia, B. et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719-729 (2006).
27. CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am. J. Hum. Genet. 74, 1175-1182 (2004).
28. Vahteristo, P. et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71, 432-438 (2002).
29. Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749-1753 (1995).
30. Thompson, D. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl. Cancer Inst. 97, 813-822 (2005).
31. Howlett, N.G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609 (2002).
32. Reid, S. et al. Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J. Med. Genet. 42, 147-151 (2005).
33. Levitus, M. et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat. Genet. 37, 934-935 (2005).
34. Reid, S. et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 39, 162-164 (2007).
35. Xia, B. et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet. 39, 159-161 (2007).
36. Levran, O. et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat. Genet. 37, 931-933 (2005).
37. Seal, S. et al. Evaluation of Fanconi anemia genes in familial breast cancer predisposition. Cancer Res. 63, 8596-8599 (2003).
38. van Puijenbroek, M. et al. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. J. Pathol. 206, 198-204 (2005).
39. Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J. Natl. Cancer Inst. 98, 1382-1396 (2006).
40. Cox, A. et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39, 352-358 (2007).
41. Amundadottir, L.T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652-658 (2006).
42. Gudmundsson, J. et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631-637 (2007).
43. Haiman, C.A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638-644 (2007).
44. Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645-649 (2007).
45. Haiman, C.A. et al. A common genetic risk factor for colorectal and prostate cancer. Nat. Genet. 39, 954-956 (2007).
46. Tomlinson, I. et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 39, 984-988 (2007).
47. Zanke, B.W. et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39, 989-994 (2007).
48. Pollock, P.M. et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26, 7158-7162 (2007).
49. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
50. Honrado, E., Benitez, J. & Palacios, J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit. Rev. Oncol. Hematol. 59, 27-39 (2006).
51. Heikkinen, K. et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27, 1593-1599 (2006).
52. Tommiska, J. et al. Evaluation of RAD50 in familial breast cancer predisposition. Int. J. Cancer 118, 2911-2916 (2006).
53. Pharoah, P.D. et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31, 33-36 (2002).
54. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
55. Domchek, S.M. & Weber, B.L. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25, 5825-5831 (2006).